Universität zu Köln

Timmer, Marco, Werner, Jan-Michael, Roehn, Gabriele, Ortmann, Monika, Blau, Tobias, Cramer, Christina, Stavrinou, Pantelis ORCID: 0000-0001-8653-1395, Krischek, Boris, Mallman, Peter and Goldbrunner, Roland (2017). Discordance and Conversion Rates of Progesterone-, Estrogen-, and HER2/neu-Receptor Status in Primary Breast Cancer and Brain Metastasis Mainly Triggered by Hormone Therapy. Anticancer Res., 37 (9). S. 4859 - 4866. ATHENS: INT INST ANTICANCER RESEARCH. ISSN 1791-7530

Full text not available from this repository.

Abstract

Background/Aim: Knowing the molecular footprint of tumors is a precondition for personalized medicine. For breast cancer, targeted therapies are frequently based on the molecular status of the tissue gained from the primary tumor operation. However, it is unclear whether metastases in different organs maintain the same status. Patients and Methods: We compared the estrogen-(ER), progesterone-(PgR) and HER2/neu receptor status of the primary tumor with brain metastases in a series of 24 consecutive breast cancer patients. Results: 62.5-75% of patients exhibited a constant receptor status between the primary tumor and the brain metastasis, whereas discordance rates of 25-37.5% were found, depending on the receptor. The rate of ER and PgR expression was each 41.6% in the primary tumors and decreased to 12.5% and 16.6% in the brain metastases. In contrast, the rate for Her2+ tumors increased from 41.6% in primary breast cancer to 65.2% in the respective brain metastases. The Ki-67 proliferation index increased significantly from a mean of 21% at the primary tumor site to 60% in brain metastases (p<0.001). All anti-estrogen treated breast tumors lost the estrogen receptor expression in the brain metastases, whereas no Her2/neu conversions occurred after treatment with trastuzumab. Conclusion: In summary, receptor conversion is frequent during disease progression. Therefore, the receptor status of the primary tumor is invalid for planning a therapy targeted against brain metastases, especially after hormone-therapy. In these cases, new tissue collection by biopsy or resection is mandatory for the selection of adequate therapeutic targets and accurate decision-making for systemic therapies.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Timmer, Marco UNSPECIFIED UNSPECIFIED UNSPECIFIED Werner, Jan-Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Roehn, Gabriele UNSPECIFIED UNSPECIFIED UNSPECIFIED Ortmann, Monika UNSPECIFIED UNSPECIFIED UNSPECIFIED Blau, Tobias UNSPECIFIED UNSPECIFIED UNSPECIFIED Cramer, Christina UNSPECIFIED UNSPECIFIED UNSPECIFIED Stavrinou, Pantelis UNSPECIFIED orcid.org/0000-0001-8653-1395 UNSPECIFIED Krischek, Boris UNSPECIFIED UNSPECIFIED UNSPECIFIED Mallman, Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED Goldbrunner, Roland UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-218367
DOI:	10.21873/anticanres.11894
Journal or Publication Title:	Anticancer Res.
Volume:	37
Number:	9
Page Range:	S. 4859 - 4866
Date:	2017
Publisher:	INT INST ANTICANCER RESEARCH
Place of Publication:	ATHENS
ISSN:	1791-7530
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language NEOADJUVANT CHEMOTHERAPY; HER-2/NEU STATUS; EXPRESSION; RECEPTORS; IMPACT; HER2; CARCINOMA; SUBSET; TUMORS Multiple languages Oncology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/21836